|
1
|
Marra M, Sordelli IM, Lombardi A, Lamberti
M, Tarantino L, Giudice A, Stiuso P, Abbruzzese A, Sperlongano R,
Accardo M, et al: Molecular targets and oxidative stress biomarkers
in hepatocellular carcinoma: An overview. J Transl Med. 9:1712011.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Czaja AJ: Hepatic inflammation and
progressive liver fibrosis in chronic liver disease. World J
Gastroenterol. 20:2515–2532. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kershenobich Stalnikowitz D and Weissbrod
AB: Liver fibrosis and inflammation. A review. Ann Hepatol.
2:159–163. 2003.PubMed/NCBI
|
|
5
|
Li S, Tan H-Y, Wang N, Zhang ZJ, Lao L,
Wong CW and Feng Y: The role of oxidative stress and antioxidants
in liver diseases. Int J Mol Sci. 16:26087–26124. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Seki E and Schwabe RF: Hepatic
inflammation and fibrosis: Functional links and key pathways.
Hepatology. 61:1066–1079. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zhang L, Song HY and Ji G: The joint
pathway of metabolism and inflammation in nonalcoholic fatty liver
disease. Zhonghua Gan Zang Bing Za Zhi. 19:395–397. 2011.(In
Chinese). PubMed/NCBI
|
|
8
|
Shivappa N, Hébert JR, Polesel J,
Zucchetto A, Crispo A, Montella M, Franceschi S, Rossi M, La
Vecchia C and Serraino D: Inflammatory potential of diet and risk
for hepatocellular cancer in a case-control study from Italy. Br J
Nutr. 115:324–331. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Alzahrani B, Isel TJ and Hebbard LW:
Non-viral causes of liver cancer: Does obesity led inflammation
play a role? Cancer Lett. 345:223–229. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhang LJ and Wang XZ: Interleukin-10 and
chronic liver disease. World J Gastroenterol. 12:1681–1685. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Budhu A and Wang XW: The role of cytokines
in hepatocellular carcinoma. J Leukoc Biol. 80:1197–1213. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Grivennikov SI, Greten FR and Karin M:
Immunity, inflammation, and cancer. Cell. 140:883–899. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wan S, Zhao E, Kryczek I, Vatan L,
Sadovskaya A, Ludema G, Simeone DM, Zou W and Welling TH:
Tumor-associated macrophages produce interleukin 6 and signal via
STAT3 to promote expansion of human hepatocellular carcinoma stem
cells. Gastroenterology. 147:1393–1404. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Hatting M, Spannbauer M, Peng J, Al
Masaoudi M, Sellge G, Nevzorova YA, Gassler N, Liedtke C, Cubero FJ
and Trautwein C: Lack of gp130 expression in hepatocytes attenuates
tumor progression in the DEN model. Cell Death Dis. 6:e16672015.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Yamazaki K, Masugi Y and Sakamoto M:
Molecular pathogenesis of hepatocellular carcinoma: Altering
transforming growth factor-β signaling in hepatocarcinogenesis. Dig
Dis. 29:284–288. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Mamiya T, Yamazaki K, Masugi Y, Mori T,
Effendi K, Du W, Hibi T, Tanabe M, Ueda M, Takayama T, et al:
Reduced transforming growth factor-beta receptor II expression in
hepatocellular carcinoma correlates with intrahepatic metastasis.
Lab Invest. 90:1339–1345. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Korkaya H, Kim GI, Davis A, Malik F, Henry
NL, Ithimakin S, Quraishi AA, Tawakkol N, D'Angelo R, Paulson AK,
et al: Activation of an IL6 inflammatory loop mediates trastuzumab
resistance in HER2+ breast cancer by expanding the
cancer stem cell population. Mol Cell. 47:570–584. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Milagre CS, Gopinathan G, Everitt G,
Thompson RG, Kulbe H, Zhong H, Hollingsworth RE, Grose R, Bowtell
DD, Hochhauser D, et al: Adaptive upregulation of EGFR limits
attenuation of tumor growth by neutralizing IL6 antibodies, with
implications for combined therapy in ovarian cancer. Cancer Res.
75:1255–1264. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Freudlsperger C, Bian Y, Contag Wise S,
Burnett J, Coupar J, Yang X, Chen Z and Van Waes C: TGF-β and NF-κB
signal pathway cross-talk is mediated through TAK1 and SMAD7 in a
subset of head and neck cancers. Oncogene. 32:1549–1559. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lin L, Amin R, Gallicano GI, Glasgow E,
Jogunoori W, Jessup JM, Zasloff M, Marshall JL, Shetty K, Johnson
L, et al: The STAT3 inhibitor NSC 74859 is effective in
hepatocellular cancers with disrupted TGF-beta signaling. Oncogene.
28:961–972. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Bajaj JS, Hylemon PB and Younossi Z: The
intestinal microbiota and liver disease. Am J Gastroenterol Suppl.
1:9–14. 2012. View Article : Google Scholar
|
|
22
|
Juárez-Hernández E, Chávez-Tapia NC, Uribe
M and Barbero-Becerra VJ: Role of bioactive fatty acids in
nonalcoholic fatty liver disease. Nutr J. 15:722016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Sharma V, Garg S and Aggarwal S:
Probiotics and liver disease. Perm J. 17:62–67. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Endo H, Niioka M, Kobayashi N, Tanaka M
and Watanabe T: Butyrate-producing probiotics reduce nonalcoholic
fatty liver disease progression in rats: New insight into the
probiotics for the gut-liver axis. PLoS One. 8:e633882013.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Mattace Raso G, Simeoli R, Russo R, Iacono
A, Santoro A, Paciello O, Ferrante MC, Canani RB, Calignano A and
Meli R: Effects of sodium butyrate and its synthetic amide
derivative on liver inflammation and glucose tolerance in an animal
model of steatosis induced by high fat diet. PLoS One.
8:e686262013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Meijer K, de Vos P and Priebe MG: Butyrate
and other short-chain fatty acids as modulators of immunity: What
relevance for health? Curr Opin Clin Nutr Metab Care. 13:715–721.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Clemente JC, Ursell LK, Parfrey LW and
Knight R: The impact of the gut microbiota on human health: An
integrative view. Cell. 148:1258–1270. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Saito H, Morizane T, Watanabe T, Kagawa T,
Miyaguchi S, Kumagai N and Tsuchiya M: Differentiating effect of
sodium butyrate on human hepatoma cell lines PLC/PRF/5, HCC-M and
HCC-T. Int J Cancer. 48:291–296. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Banasiewicz T, Krokowicz Ł, Stojcev Z,
Kaczmarek BF, Kaczmarek E, Maik J, Marciniak R, Krokowicz P,
Walkowiak J and Drews M: Microencapsulated sodium butyrate reduces
the frequency of abdominal pain in patients with irritable bowel
syndrome. Colorectal Dis. 15:204–209. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wu J and Zern MA: Modification of
liposomes for liver targeting. J Hepatol. 24:757–763. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Rosso F, Quagliariello V, Tortora C, Di
Lazzaro A, Barbarisi A and Iaffaioli RV: Cross-linked hyaluronic
acid sub-micron particles: In vitro and in vivo biodistribution
study in cancer xenograft model. J Mater Sci Mater Med.
24:1473–1481. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Vecchione R, Iaccarino G, Bianchini P,
Marotta R, D'autilia F, Quagliariello V, Diaspro A and Netti PA:
Ultrastable liquid-liquid interface as viable route for controlled
deposition of biodegradable polymer nanocapsules. Small.
12:3005–3013. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Caraglia M, Marra M, Misso G, Lamberti M,
Salzano G, De Rosa G and Abbruzzese A: Tumour-specific uptake of
anti-cancer drugs: The future is here. Curr Drug Metab. 13:4–21.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Camilleri JP, Williams AS, Amos N,
Douglas-Jones AG, Love WG and Williams BD: The effect of free and
liposome-encapsulated clodronate on the hepatic mononuclear
phagocyte system in the rat. Clin Exp Immunol. 99:269–275. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Van Rooijen N and Sanders A: Kupffer cell
depletion by liposome-delivered drugs: Comparative activity of
intracellular clodronate, propamidine, and
ethylenediaminetetraacetic acid. Hepatology. 23:1239–1243. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Vecchione R, Quagliariello V, Calabria D,
Calcagno V, De Luca E, Iaffaioli RV and Netti PA: Curcumin
bioavailability from oil in water nano-emulsions: In vitro and in
vivo study on the dimensional, compositional and interactional
dependence. J Control Release. 233:88–100. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Sasaki A, Murahashi N, Yamada H and
Morikawa A: Syntheses of novel galactosyl ligands for liposomes and
their accumulation in the rat liver. Biol Pharm Bull. 17:680–685.
1994. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Watanabe M, Pesando JM and Hakomori S:
Effect of liposomes containing sodium butyrate conjugated with
anti-CD19 monoclonal antibody on in vitro and in vivo growth of
malignant lymphoma. Cancer Res. 50:3245–3248. 1990.PubMed/NCBI
|
|
39
|
Altieri F, Di Stadio CS, Severino V,
Sandomenico A, Minopoli G, Miselli G, Di Maro A, Ruvo M, Chambery
A, Quagliariello V, et al: Anti-amyloidogenic property of human
gastrokine 1. Biochimie. 106:91–100. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Di Stadio CS, Altieri F, Miselli G, Elce
A, Severino V, Chambery A, Quagliariello V, Villano V, de Dominicis
G, Rippa E, et al: AMP18 interacts with the anion exchanger SLC26A3
and enhances its expression in gastric cancer cells. Biochimie.
121:151–160. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Baravalle G, Schober D, Huber M, Bayer N,
Murphy RF and Fuchs R: Transferrin recycling and dextran transport
to lysosomes is differentially affected by bafilomycin, nocodazole,
and low temperature. Cell Tissue Res. 320:99–113. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Barbarisi M, Iaffaioli RV, Armenia E,
Schiavo L, De Sena G, Tafuto S, Barbarisi A and Quagliariello V:
Novel nanohydrogel of hyaluronic acid loaded with quercetin alone
and in combination with temozolomide as new therapeutic tool, CD44
targeted based, of glioblastoma multiforme. J Cell Physiol.
233:6550–6564. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Qaddoumi MG, Gukasyan HJ, Davda J,
Labhasetwar V, Kim KJ and Lee VH: Clathrin and caveolin-1
expression in primary pigmented rabbit conjunctival epithelial
cells: Role in PLGA nanoparticle endocytosis. Mol Vis. 9:559–568.
2003.PubMed/NCBI
|
|
44
|
Huang M, Ma Z, Khor E and Lim LY: Uptake
of FITC-chitosan nanoparticles by A549 cells. Pharm Res.
19:1488–1494. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Quagliariello V, Iaffaioli RV, Armenia E,
Clemente O, Barbarisi M, Nasti G, Berretta M, Ottaiano A and
Barbarisi A: Hyaluronic acid nanohydrogel loaded with quercetin
alone or in combination to a macrolide derivative of rapamycin
RAD001 (Everolimus) as a new treatment for hormone-responsive human
breast cancer. J Cell Physiol. 232:2063–2074. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Nagasaki T, Hara M, Nakanishi H, Takahashi
H, Sato M and Takeyama H: Interleukin-6 released by colon
cancer-associated fibroblasts is critical for tumour angiogenesis:
anti-interleukin-6 receptor antibody suppressed angiogenesis and
inhibited tumour-stroma interaction. Br J Cancer. 110:469–478.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Meng J, Guo F, Xu H, Liang W, Wang C and
Yang XD: Combination therapy using co-encapsulated resveratrol and
paclitaxel in liposomes for drug resistance reversal in breast
cancer cells in vivo. Sci Rep. 6:223902016. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Gillet R, Jeannesson P, Sefraoui H,
Arnould-Guérin ML, Kirkiacharian S, Jardillier JC and Pieri F:
Piperazine derivatives of butyric acid as differentiating agents in
human leukemic cells. Cancer Chemother Pharmacol. 41:252–255. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Siregar C, Wasito EB and Sudiana IK:
Effect of butyric acid on p53 expression and apoptosis in colon
epithelial cells in mice after treated with
9,10-dimethyl-1,2-benz(a)anthracene. Procedia Chem. 18:141–146.
2016. View Article : Google Scholar
|
|
50
|
Coradini D and Speranza A: Histone
deacetylase inhibitors for treatment of hepatocellular carcinoma.
Acta Pharmacol Sin. 26:1025–1033. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Wang HG, Huang XD, Shen P, Li LR, Xue HT
and Ji GZ: Anticancer effects of sodium butyrate on hepatocellular
carcinoma cells in vitro. Int J Mol Med. 31:967–974. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Caraglia M, De Rosa G, Salzano G, Santini
D, Lamberti M, Sperlongano P, Lombardi A, Abbruzzese A and Addeo R:
Nanotech revolution for the anti-cancer drug delivery through
blood-brain barrier. Curr Cancer Drug Targets. 12:186–196. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Dash M, Chiellini F, Ottenbrite RM and
Chiellini E: Chitosan - A versatile semi-synthetic polymer in
biomedical applications. Prog Polym Sci. 36:981–1014. 2011.
View Article : Google Scholar
|
|
54
|
Wu CY, Chen YJ, Ho HJ, Hsu YC, Kuo KN, Wu
MS and Lin JT: Association between nucleoside analogues and risk of
hepatitis B virus–related hepatocellular carcinoma recurrence
following liver resection. JAMA. 308:1906–1914. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S,
Kim JS, Luo R, Feng J, Ye S, Yang TS, et al: Efficacy and safety of
sorafenib in patients in the Asia-Pacific region with advanced
hepatocellular carcinoma: A phase III randomised, double-blind,
placebo-controlled trial. Lancet Oncol. 10:25–34. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Park SY, Han J, Kim JB, Yang MG, Kim YJ,
Lim HJ, An SY and Kim JH: Interleukin-8 is related to poor
chemotherapeutic response and tumourigenicity in hepatocellular
carcinoma. Eur J Cancer. 50:341–350. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Ren Y, Poon RT, Tsui HT, Chen WH, Li Z,
Lau C, Yu WC and Fan ST: Interleukin-8 serum levels in patients
with hepatocellular carcinoma: Correlations with
clinicopathological features and prognosis. Clin Cancer Res.
9:5996–6001. 2003.PubMed/NCBI
|
|
58
|
Theron AJ, Anderson R, Rossouw TM and
Steel HC: The role of transforming growth factor beta-1 in the
progression of HIV/AIDS and development of non-AIDS-defining
fibrotic disorders. Front Immunol. 8:14612017. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Ungerleider N, Han C, Zhang J, Yao L and
Wu T: TGFβ signaling confers sorafenib resistance via induction of
multiple RTKs in hepatocellular carcinoma cells. Mol Carcinog.
56:1302–1311. 2017. View Article : Google Scholar : PubMed/NCBI
|
